Sponsors › Eli Lilly

Eli Lilly

Every GLP‑1 and incretin trial, approval and scheduled result we hold for Eli Lilly, drawn from ClinicalTrials.gov and Drugs@FDA.

Eli Lilly is a commercial sponsor with 132 trials in the incretin class on file here, across 8 molecules. The programme is split between 24 early-stage trials and 108 in phase 3 or later. 53 approved FDA submissions sit against this sponsor in Drugs@FDA. The next scheduled result is 2026-10.

Molecules

dulaglutide · exenatide · liraglutide · mazdutide · orforglipron · retatrutide · semaglutide · tirzepatide

Trials on file

132

Active trials

46

Results scheduled

32

Approved FDA submissions

53

Results due

FDA record

Trials on file

All 132 incretin trials recorded for this sponsor, active first.